Transgene S.A.
Transgene S.A. (0OCQ.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Transgene S.A. (0OCQ.L), featuring income statements, balance sheets, and cash flow data.
Transgene S.A. (0OCQ.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Transgene S.A. 0OCQ.L financial performance.
| Metric | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $23000.00 | $1.57M | $1.57M | $1.16M |
| Cost of Revenue | $0.00 | $7.010M | $7.010M | $7.78M |
| Gross Profit | $23000.00 | -$5.44M | -$5.44M | -$6.63M |
| Gross Profit Ratio | $1.00 | -$3.47 | -$3.47 | -$5.73 |
| R&D Expenses | $14.83M | $8.66M | $8.66M | $14.79M |
| SG&A Expenses | $4.54M | $1.87M | $1.87M | $3.22M |
| Operating Expenses | $19.25M | $1.92M | $1.92M | $18.02M |
| Total Costs & Expenses | $19.85M | $8.93M | $8.93M | $18.82M |
| Interest Income | $311000.00 | $0.00 | $3.75M | $249000.00 |
| Interest Expense | $542000.00 | $0.00 | $0.00 | $39000.00 |
| Depreciation & Amortization | $606000.00 | $607500.00 | $607500.00 | $803000.00 |
| EBITDA | -$18.54M | -$8.50M | -$6.73M | -$18.52M |
| EBITDA Ratio | -$806.26 | -$4.29 | -$4.29 | -$14.59 |
| Operating Income | -$19.83M | -$7.34M | -$7.34M | -$17.66M |
| Operating Income Ratio | -$862.13 | -$4.68 | -$4.68 | -$15.28 |
| Other Income/Expenses (Net) | $137000.00 | -$2.07M | $4.13M | -$1.70M |
| Income Before Tax | -$19.69M | -$3.21M | -$3.21M | -$19.37M |
| Income Before Tax Ratio | -$856.17 | -$2.05 | -$2.05 | -$16.75 |
| Income Tax Expense | -$3.21M | -$2.98M | $0.00 | -$3.46M |
| Net Income | -$16.48M | -$3.21M | -$3.21M | -$15.90M |
| Net Income Ratio | -$716.74 | -$2.05 | -$2.05 | -$13.76 |
| EPS | -$0.16 | -$0.03 | -$0.03 | -$0.16 |
| Diluted EPS | -$0.16 | -$0.03 | -$0.03 | -$0.16 |
| Weighted Avg Shares Outstanding | $100.96M | $101.39M | $101.39M | $99.80M |
| Weighted Avg Shares Outstanding (Diluted) | $100.96M | $101.38M | $101.38M | $99.80M |
Over the last four quarters, Transgene S.A. achieved steady financial progress, growing revenue from $1.16M in Q2 2023 to $23000.00 in Q2 2024. Gross profit stayed firm with margins at 100% in Q2 2024 versus -573% in Q2 2023. Operating income totaled -$19.83M in Q2 2024, maintaining a -86213% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$18.54M. Net income dropped to -$16.48M, with EPS at -$0.16. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan